Literature DB >> 28073817

Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies.

Haruki Koike1, Masato Kadoya2, Ken-Ichi Kaida2, Shohei Ikeda1, Yuichi Kawagashira1, Masahiro Iijima1, Daisuke Kato3, Hidenori Ogata4, Ryo Yamasaki4, Noriyuki Matsukawa3, Jun-Ichi Kira4, Masahisa Katsuno1, Gen Sobue1,5.   

Abstract

OBJECTIVE: To investigate the morphological features of chronic inflammatory demyelinating polyneuropathy (CIDP) with autoantibodies directed against paranodal junctional molecules, particularly focusing on the fine structures of the paranodes.
METHODS: We assessed sural nerve biopsy specimens obtained from 9 patients with CIDP with anti-neurofascin-155 antibodies and 1 patient with anti-contactin-1 antibodies. 13 patients with CIDP without these antibodies were also examined to compare pathological findings.
RESULTS: Characteristic light and electron microscopy findings in transverse sections from patients with anti-neurofascin-155 and anti-contactin-1 antibodies indicated a slight reduction in myelinated fibre density, with scattered myelin ovoids, and the absence of macrophage-mediated demyelination or onion bulbs. Teased-fibre preparations revealed that segmental demyelination tended to be found in patients with relatively higher frequencies of axonal degeneration and was tandemly found at consecutive nodes of Ranvier in a single fibre. Assessment of longitudinal sections by electron microscopy revealed that detachment of terminal myelin loops from the axolemma was frequently found at the paranode in patients with anti-neurofascin-155 and anti-contactin-1 antibody-positive CIDP compared with patients with antibody-negative CIDP. Patients with anti-neurofascin-155 antibodies showed a positive correlation between the frequencies of axo-glial detachment at the paranode and axonal degeneration, as assessed by teased-fibre preparations (p<0.05).
CONCLUSIONS: Paranodal dissection without classical macrophage-mediated demyelination is the characteristic feature of patients with CIDP with autoantibodies to paranodal axo-glial junctional molecules. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28073817     DOI: 10.1136/jnnp-2016-314895

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  48 in total

Review 1.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 2.  Mechanisms of node of Ranvier assembly.

Authors:  Matthew N Rasband; Elior Peles
Journal:  Nat Rev Neurosci       Date:  2020-11-25       Impact factor: 34.870

Review 3.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

Review 4.  Immunopathological Factors Associated with Disability in Multiple Sclerosis.

Authors:  Erdem Tüzün
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

5.  Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo.

Authors:  Constance Manso; Luis Querol; Cinta Lleixà; Mallory Poncelet; Mourad Mekaouche; Jean-Michel Vallat; Isabel Illa; Jérôme J Devaux
Journal:  J Clin Invest       Date:  2019-03-14       Impact factor: 14.808

Review 6.  Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

Authors:  Lisha Tang; Qianyi Huang; Zhen Qin; Xiangqi Tang
Journal:  J Neurol       Date:  2020-04-07       Impact factor: 4.849

Review 7.  Association between chronic inflammatory demyelinating polyneuropathy and gastrointestinal malignancies.

Authors:  Adnan Malik; Rani Berry; Brian M Fung; James H Tabibian
Journal:  Clin J Gastroenterol       Date:  2020-11-04

Review 8.  Modeling chemotherapy induced peripheral neuropathy (CIPN) in vitro: Prospects and limitations.

Authors:  Helmar C Lehmann; Nathan P Staff; Ahmet Hoke
Journal:  Exp Neurol       Date:  2019-12-05       Impact factor: 5.330

Review 9.  Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations.

Authors:  Ze Wang; Xiajun Zhou; Nan Zhao; Chong Xie; Desheng Zhu; Yangtai Guan
Journal:  Neurol Sci       Date:  2021-03-29       Impact factor: 3.307

Review 10.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.